Source - Alliance News

Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

The London-based biopharmaceutical company focused on treatments for deadly blood diseases said the submission was for HEMO-CAR-T, an immunotherapy for the potential treatment of acute myeloid leukaemia, a cancer of the white blood cells. ‘Acute’ means it progresses quickly and aggressively.

A complete response is a requirement for the clinical hold to be lifted, needed to obtain consent from the FDA to start phase 1 clinical trials.

Chief Executive Officer Vladislav Sandler said: ‘We are pleased to have filed a complete response to the FDA addressing their concerns that resulted in a CH of the HEMO-CAR-T IND. We look forward to becoming a clinical stage biopharmaceutical company once consent is received from the FDA.’

Hemogenyx shares rose 3.3% to 2.27 pence each on Tuesday morning in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Hemogenyx Pharmaceuticals PLC (HEMO)

+0.02p (+1.37%)
delayed 15:52PM